Invited commentary--prescription drug label adverse events: a call for prioritization: comment on "A quantitative analysis of adverse events and 'overwarning' in drug labeling"

Arch Intern Med. 2011 May 23;171(10):946-7. doi: 10.1001/archinternmed.2011.200.
No abstract available

Publication types

  • Comment

MeSH terms

  • Adverse Drug Reaction Reporting Systems / standards*
  • Adverse Drug Reaction Reporting Systems / trends
  • Drug Labeling / standards*
  • Drug Labeling / trends
  • Drug Prescriptions / standards
  • Evaluation Studies as Topic*
  • Humans
  • Total Quality Management
  • United States
  • United States Food and Drug Administration